Conclusions Crizotinib proved highly effective in pts with METmut aNSCLC, with a manageable toxicity profile. Additional research is warranted to identify biomarkers for response.

over 1 year ago

Clinical • Metastases

ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

MET exon 14 mutation • MET mutation • MET H1094Y

Xalkori (crizotinib)

almost2years

Activating MET Kinase Domain Mutations Deﬁne a Novel Targetable Molecular Subtype of Non-small Cell Lung Cancer that is Clinically Sensitive to MET Inhibitor Elzovantinib (TPX-0022) (IASLC-TTLC 2023)

"CONCLUSION Activating MET TKD mutations without concurrent MET exon 14 mutations were detected in ~ 0.2% of NSCLC, and occur in the absence of other known drivers in a subset of cases. Comprehensive genomic profiling to detect these alterations and guide treatment selection and clinical trial enrollment is warranted."

almost 2 years ago

Clinical

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • MET amplification • EGFR amplification • MET exon 14 mutation • MET H1094Y • MET D1228N • MET F1200I

elzovantinib (TPX-0022)

almost2years

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. (PubMed, Respir Res)

MET TKD mutations were identified in both baseline and patients treated with TKIs. MET-H1094Y might play an oncogenic role in NSCLC and may confer acquired resistance to EGFR-TKIs. Preliminary data indicates that EGFR-mutated NSCLC patients who acquired MET-V1092I or MET-H1094Y may benefit from combinatorial therapy with EGFR-TKI and MET-TKI, providing insights into personalized medical treatment.

almost 2 years ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase)

EGFR mutation • MET amplification • MET exon 14 mutation • MET mutation • MET H1094Y • MET D1228N • MET D1228H • MET Y1230C